Company news

Orchestra Biomed Holdings, Inc. (NASDAQ:OBIO) news

Orchestra Biomed Holdings, Inc. news releases on 6ix. Latest, Oct 1, 2026: Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal…

Orchestra Biomed Holdings, Inc. (NASDAQ:OBIO) news

Press releases & updates

Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy

Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026

Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026

Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics

Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Orchestra BioMed to Host Business Update Call on November 12, 2025

Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements

Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial

OBIO® Introduces the Future Female Leaders in Life Sciences

Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit

Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout

Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology

Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction

Campbellford Memorial Hospital’s New Homecare Program Frees up 14.5 Hospital Bed-Days Per Patient Through a Partnership With Gotcare and OBIO®

Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility

Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings

Orchestra BioMed Announces Pricing of $40 Million Public Offering

Orchestra BioMed Announces Proposed Public Offering

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

OBIO® Paves the Way for Companies to Succeed in Canada as a Stepping Stone to New Global Markets

Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

Orchestra BioMed to Present at Upcoming Investor Conferences

Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference

Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

Orchestra BioMed Announces AVIM Therapy Program Presentations at ICI Meeting

Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference

Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update

Orchestra BioMed to Participate in Jefferies London Healthcare Conference